Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is set to release its earnings data before the market opens on Thursday, July 27th. Analysts expect Sunesis Pharmaceuticals to post earnings of ($0.59) per share for the quarter.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.36. The company had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.57 million. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS. On average, analysts expect Sunesis Pharmaceuticals to post $-2.02 EPS for the current fiscal year and $-1.60 EPS for the next fiscal year.

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ SNSS) opened at 2.56 on Thursday. The stock has a 50 day moving average price of $2.84 and a 200 day moving average price of $3.59. Sunesis Pharmaceuticals, Inc. has a 12-month low of $2.51 and a 12-month high of $6.30. The firm’s market cap is $54.94 million.

Several research firms have weighed in on SNSS. Cantor Fitzgerald reissued a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Tuesday, May 2nd. Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Thursday, May 11th.

COPYRIGHT VIOLATION NOTICE: “Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.